

WHAT IS CLAIMED IS:

1. A prognosticative method for determining the effectiveness of secretin administration for the treatment of an individual diagnosed with a pervasive development disorder (PDD), comprising the steps of:

5 obtaining a sample of feces from an individual;
determining a quantitative level of chymotrypsin present in the sample; and
correlating the quantitative level of chymotrypsin determined to be present
10 in the sample with the PDD to determine the efficacy of treating the individual with secretin administration.

2. The method of claim 1, wherein the step of correlating comprises
comparing the quantitative level of chymotrypsin present in the sample with at
least one threshold chymotrypsin level to determine the efficacy of secretin
administration to the individual.

15 3. The method of claim 2, wherein the at least one threshold chymotrypsin level is based on a level of chymotrypsin associated with individuals of the same approximate age that are not diagnosed as having the PDD.

4. The method of claim 1, wherein the step of determining a quantitative level of chymotrypsin is performed by an enzymatic photospectrophotometry analysis.

5 5. The method of claim 1, wherein the PDD is autism, ADD (attention deficit disorder), ADHD (attention deficit hyperactivity disorder) or Aspergers.

6. A therapeutic method for treating an individual diagnosed with a pervasive development disorder (PDD), comprising the steps of:

determining the efficacy of secretin administration for the treatment of the individual based on a measure of the individual's chymotrypsin level; and

10 administering secretin therapy to the individual based on the determination of the measure of the individual's chymotrypsin level.

7. The method of claim 6, wherein the step of determining the efficacy of secretin administration comprises the steps of:

obtaining a sample of feces from the individual;

15 determining a quantitative level of chymotrypsin present in the sample; and

correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin administration.

5 8. The method of claim 7, wherein the step of correlating comprises comparing the quantitative level of chymotrypsin present in the sample with at least one threshold chymotrypsin level to determine the efficacy of secretin administration to the individual.

10 9. The method of claim 8, wherein the at least one threshold chymotrypsin level is based on a level of chymotrypsin associated with individuals that are not diagnosed as having the PDD.

10. The method of claim 8, wherein the at least one threshold chymotrypsin level is 8.4 U/gm..

11. The method of claim 8, wherein the at least one threshold chymotrypsin level is 4.2 U/gm.

12. The method of claim 7, wherein the step of determining a quantitative level of chymotrypsin is performed by an enzymatic photospectrophotometry analysis.

13. The method of claim 6, wherein the PDD is autism, ADD (attention deficit disorder), ADHD (attention deficit hyperactivity disorder) or Aspergers.

14. The method of claim 6, wherein the step of administering secretin therapy to the individual comprises the steps of:

administering a therapeutic dose of secretin to the individual at each of a first time interval; and

measuring the individuals chymotrypsin level at each of a predetermined second time interval.

15. The method of claim 14, wherein the first time interval is 6 weeks and the therapeutic dose is 1 U/kg.

16. The method of claim 15, further comprising the steps of testing the individual pre-secretin administration and post secretin administration to determine if the PDD has improved.

17. A therapeutic method of treating an individual diagnosed with a pervasive developmental disorder (PDD), comprising of the steps of:

determining the efficacy of digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level; and

administering digestive enzyme therapy to the individual based on the determination of the measure of the individual's chymotrypsin level.

18. The method of claim 17, wherein the PDD is autism, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD) or aspergers.

19. The method of claim 17, wherein the step of determining the efficacy of digestive enzyme administration comprises the steps of:

obtaining a sample of feces from the individual;

determining a quantitative level of chymotrypsin present in the sample; and

correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with digestive enzymes.

20. The method of claim 19, wherein the step of correlating comprises comparing the quantitative level of chymotrypsin present in the sample with at least one threshold chymotrypsin level to determine the efficacy of digestive enzyme administration to the individual.

5 21. The method of claim 20, wherein the at least one threshold chymotrypsin level is 8.4 U/gm.

22. The method of claim 20, wherein the at least one threshold chymotrypsin level is 4.2 U/gm.

10 23. The method of claim 17, wherein the step of administering digestive enzymes to the individual comprises the steps of:
administering a therapeutic dose of digestive enzymes at each meal; and
measuring the individual's chymotrypsin level at each of a predetermined first interval.

15 24. The method of claim 23, further comprising the steps of testing the individual pre-digestive enzyme administration and post -digestive enzyme administration to determine if the PDD has improved.

Add a2